

Pain and Opioid Management Resources

Compiled by Stephen Wright, MD¹, J. Scott Bainbridge, MD², and Jonathan Clapp, MD³

On behalf of the

Colorado Pain Society

And

Consultant: Medical Pain Management / Addiction¹

MindYourPain², Denver Back Pain Specialists²

Colorado Pain Consultants³

Pain / Opioid Management:

Colorado Consortium for Prescription Drug Abuse Prevention (CCPDAP) [site](#)

American Academy of Pain Medicine www.painmed.org

American Pain Society <http://americanpainsociety.org/>

[Washington State Agency Medical Director's Group](#)

Guidelines for the Use of Opioids:

2014 CO DORA Policy for Prescribing and Dispensing Opioids [document](#)

2018 CO DORA Opioid Policy is now under public review and comment

[Federation of State Medical Boards 2017 Guidelines for the Chronic Use of Opioid Analgesics](#)

Colorado ACEP 2017 Opioid Prescribing and Treatment Guidelines [document](#)

CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016 [CDC Guideline](#)

Pain Management and Opioid Prescribing Training and Educational Sites:

CCPDAP Provider Education [site](#)

SCOPE of Pain. Safe & Competent Opioid Prescribing Education

<https://www.scopeofpain.com/online-training/>

The Dannemiller pain course:

<https://cme.dannemiller.com/dvd-usb/pain/>

Academy of Integrative Medicine CME [site](#)

ECHO Pain [site](#)

Project ECHO (Extension of Community Healthcare Outcomes) [site](#)

[Center for Personalized Education for Physicians: courses \(CPEP\)](#)

[American Board of Pain Medicine Safe Opioid Prescribing Examination](#)

Substance Misuse / Medication Assisted Treatment Training:

[Screening Brief Intervention Referral to Treatment \(SBIRT\): Health Teamworks Colorado](#)

Medication Assisted Treatment:

SAMHSA Medication Assisted Treatment [site](#)

SAMHSA Buprenorphine for MAT [site](#)

DATA 2000 Buprenorphine Waiver Training <http://www.buppractice.com/>

Strategy and Position Papers:

IOM Relieving Pain in America [document](#)

NIH National Pain Strategy [document](#)

AAFP Pain Management and Opioid Abuse Position Paper [document](#)

Patient Reported Outcome Measures (PROM) / Substance Risk or Misuse Screening Tools:

[PEG-3 for pain and function](#)

[PHQ-4 for depression and anxiety](#)

PEG-3 [article](#)

Brief Pain Inventory (short form) [document](#)

PHQ-9 [document](#)

GAD-7 [document](#)

Pain Catastrophizing Scale (PCS) [document](#)

Clinically-Administered PTSD Scale for DSM-V (CAPS-5) [site](#)

[Functional and Psychological Tests - DOWC QPOP](#)

[Opioid Risk Tool \(ORT\)](#)

[CAGE-AID](#)

[CRAFFT Brief Screening Tool for Adolescents](#)

[Drug Abuse Screening Test DAST-10](#)

[Detecting Substance Abuse and Dependence: Red Flags, and Risk Factors](#)

[DSM-5 diagnostic criteria for Opioid Use Disorder](#)

[Two-Item Conjoint Screening \(TICS\) scale](#)

[Screening Brief Intervention Referral to Treatment \(SBIRT\): Health Teamworks Colorado](#)

[Fagerstrom Test for Nicotine Dependence](#)

[Alcohol Use Disorder Identification Test](#)

[Cannabis Use Disorder Identification Test - Revised](#)

[Severity of Dependence Scale \(SDS\) - for drugs](#)

[STOP-BANG sleep apnea questionnaire](#)

[Screener and Opioid Assessment for Patients with Pain \(SOAPP\) screener link](#)

[Clinical Opioid Misuse Measure \(COMM\) screener link](#)

[Addiction Behaviors Checklist](#)

Substance Use / Management:

[Colorado Prescription Drug Monitoring Program \(PDMP\)](#)

[Washington State Agency of Medical Directors Opioid Dose Calculator](#)

[Practical Pain Management Opioid MME Calculator](#)

Medication Take Back and Disposal [site](#)

[Colorado Household Medication Take-Back Program](#)

Naloxone Nasal Instructions (with phone app download):

<https://opirescue.com/>

Controlled Substance Agreement Templates:

[American Academy of Pain Medicine: Controlled Substance Agreement. 2013](#)
COPIC Medical Guidelines and Tools (including opioid agreement) [link to documents](#)
Buprenorphine Maintenance Therapy Consent [document](#)
[Example of Office-Based Opioid Treatment Policies](#)

[ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use](#)

[Washington State Agency of Medical Directors Opioid Tapering Plan](#) (and other resources)
[Clinical Opioid Withdrawal Scale](#)
[Narcotics Anonymous](#) [Alcoholics Anonymous](#) [Pills Anonymous](#)
[SAMHSA: Medication Assisted Treatment website](#)
[Buprenorphine Treatment Practitioner Locator](#)
[Opioid Treatment Program \(methadone\) Directory](#)
[Depot Naltrexone Medical Provider Locator](#)

[HIPAA](#)

[42 C.F.R Part 2 - CONFIDENTIALITY OF SUBSTANCE USE DISORDER PATIENT RECORDS](#)
[National and state-by-state pain statutes & regulations](#)
[Drug Enforcement Administration: Office of Diversion Control](#)
[Food and drug Administration: Opioids](#)
[Center for Disease Control: Guideline for Prescribing Opioids for Chronic Pain 2016](#)
[Federation of State Medical Boards: Guidelines for the Chronic Use of Opioid Analgesics 2017](#)
[North Colorado Health Alliance: Opioid Best Practice Checklist 2016](#)
[Colorado Consortium for Prescription Drug Abuse](#)
[Colorado ECHO: Chronic Pain Disease Management Program](#)
[American Society of Addiction Medicine: ER/LA prescribing Providers Clinical Support Systems Opioids \(PCSS_O\)](#)

Recommended Reading:

Books:

The American Pain Society's [Principles of Analgesic Use](#) 7th edition [link](#)

[Bonica's Management of Pain](#) [link](#)

[Comprehensive Treatment of Chronic Pain by Medical, Interventional, and Integrative Approaches: The AMERICAN ACADEMY OF PAIN MEDICINE Textbook on Patient Management](#) [link](#)

The FSMB approved book, written by pain medicine specialist Scott M. Fishman, MD:
[Responsible Opioid Prescribing: A Clinician's Guide](#) [link](#)

Additional References:

Dorflinger L, Kerns RD, Auerbach SM. **Providers'** roles in enhancing patients' adherence to pain self management. *Transl Behav Med.* 2013;3(1):39-46. [Article](#)

Manubay JM, Muchow C, Sullivan MA. Prescription drug abuse: epidemiology, regulatory issues, chronic pain management with narcotic analgesics. *Prim Care*. 2011;38(1):71-90, vi. [Article](#)

Alturi S, Akbik H, Sudarshan G. Prevention of opioid abuse in chronic non-cancer pain: an algorithmic, evidence based approach. *Pain Phys*. 2012;ES177-89. [Article](#)

Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. 2014. [Document](#)

Michna E, Ross EL, Hynes WL, et al. Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. *J Pain Symp Manage*. 2004;28(3):250-8. [Abstract](#)

Manchkanti L, Helm S, Fellows B, et al. Opioid epidemic in the United States. *Pain Phys*. 2012;15(3 Suppl):ES9-38. [Article](#)

Becker WC, Sullivan LE, Tetrault JM, et al. Non-medical use, abuse and dependence on prescription opioids among US adults: psychiatric, medical and substance use correlates. *Drug Alcohol Depend*. 2008;94:38-47. [Abstract](#)

Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. *Drug Alcohol Depend*. 2012;125(1-2):8-18. [Article](#)

Cheatle MD, Savage SR. Informed consent in opioid therapy: a potential obligation and opportunity. *J Pain Symp Manage*. 2012;44(1):105-16. [Article](#)

Downey E, Pan W, Harrison J, et al. Implementation of a Schedule II patient agreement for opioids and stimulants in an adult primary care practice. *J Family Med Prim Care*. 2017;6(1):52-57. [Article](#)

Starrels JL, Becker WC, Alford DP, et al. Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. *Ann Intern Med*. 2010;152(11):712-20. [Abstract](#)

Gourlay DL, Heit HA, Coplan YH, et al. Urine drug testing in clinical practice. 2015. PharmaCon Corp. [Monograph](#)

Hamill-Ruth RJ, Larriviere K, McMasters MG. Addition of objective data to identify risk for medication misuse and abuse: the inconsistency score. *Pain Med*. 2013;14(12):1900-7. [Abstract](#)

Lee M, Silverman SM, Hansen H, et al. A comprehensive review of opioid-induced hyperalgesia. *Pain Physician*. 2011;14(2):145-61. [Abstract](#)

Green TC, Dauria EF, Bratberg J, et al. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone. *Harm Reduct J*. 2015;12:25. [Article](#)

Green TC, Heimer R, Grau LE. Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States. *Addiction*. 2008;103(6):979-89. [Article](#)

Dwyer K, Walley AY, Langlois BK, et al. Opioid education and nasal naloxone rescue kits in the emergency department. *West J Emerg Med*. 2015;16(3):381-4. [Article](#)

Hoppe J, Howland MA, Nelson L. The role of pharmacies and pharmacists in managing controlled substance dispensing. *Pain Med*. 2014;15(12):1996-8. [Article](#)

Ashton H. The Ashton Manual. 2002. [Document](#) [Regarding benzodiazepines, including tapering]

Stanos SP, Bruckenthal P, Barkin RL. Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering. *Mayo Clin Proc*. 2012;87(7):683-94. [Article](#)

Alperstein D, Sharpe L. The efficacy of motivational interviewing in adults with chronic pain: a meta-analysis and systematic review. *J Pain*. 2016;17(4):393-403. [Abstract](#)

Dunn C, Deroo L, Rivara FP. The use of brief interventions adapted from motivational interviewing across behavioral domains: a systematic review. *Addiction*. 2001;96(12):1725-42. [Abstract](#)

Rubak S, Sandbaek A, Lauritzen T, Christensen B. Motivational interviewing: a systematic review and meta-analysis. *Br J Gen Pract*. 2005;55(513):305-12. [Abstract](#)

Barrett K, Chang YP. Behavioral interventions targeting chronic pain, depression, and substance use disorder in primary care. *J Nurs Scholarsh*. 2016;48(4):345-53. [Abstract](#)

Wiedemer NL, Harden PS, Arndt IO, Gallagher RM. The opioid renewal clinic: a primary care, managed approach to opioid therapy in chronic pain patients at risk for substance abuse. *Pain Med*. 2007;8(7):573-84. [Abstract](#)

Parchman ML, Von Korff M, Baldwin LM, et al. Primary care clinic re-design for prescription opioid management. *J Am Board Fam Med*. 2017;30(1):44-51. [Article](#)

Fudin J, Ahmed N, Horlacher R. Opioid withdrawal: a new look at medication options. *Prac Pain Manag*. 2017. [Article](#)

Diaper AM, Law FD, Melichar JK. Pharmacological strategies for detoxification. *Br J Clin Pharmacol*. 2014; 77(2): 302-14. [Article](#)

Koechl B, Unger A, Fischer G. Age-related aspects of addiction. *Gerontology*. 2012;58(6):540-4. [Article](#)

Azrin NH, McMahon PT, Donohue B, et al. Behavior therapy for drug abuse: a controlled treatment outcome study. *Behav Res Ther*. 1994;32(8):857-66. [Abstract](#)

Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the use of medications in the treatment of addiction involving opioid use. *J Addict Med* 2015; 9:358–367. [Article](#)

Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. *Health Technol Assess*. 2007;11(9):1-171, iii-iv. [Article](#)

Tanum L, Solli KK, Latif Z-H. et al. The effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. *JAMA Psych*. 2017 Oct 27 [Epub] [Article](#)

Watkins KE, Ober AJ, Lamp K, et al. Collaborative care for opioid and alcohol use disorders in primary care: the SUMMIT randomized clinical trial. *JAMA Intern Med*. 2017;177(10):1480-8. [Abstract](#)

¹ Boscarino JA, Hoffman SN, Han JJ. Opioid-use disorder among patients on long-term opioid therapy: impact of final DSM-5 diagnostic criteria on prevalence and correlates. *Subst Abuse Rehabil*. 2015;6:83-91. [Article](#)

² Vowels KE, McEntee ML, Julnes PS, et al. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. *Pain*. 2015;156(4):569-76. [Abstract](#)

³ Becker WC, Sullivan LE, Tetrault JM, et al. Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates. *Drug Alcohol Depend*. 2008;94(1-3):38-47. [Abstract](#)

⁴ Cowan DT, Wilson-Barnett J, Griffiths P, Allan LG. A survey of chronic noncancer pain patients prescribed opioid analgesics. *Pain Med*. 2003;4(4):340-51. [Abstract](#)

⁵ Edlund MJ, Martin BC, Fan MY, et al. Risks for opioid abuse and dependence among recipients of chronic opioid therapy: results from the TROUP study. *Drug Alcohol Depend*. 2010;112(1-2):90-8. [Article](#)

⁶ Fishbain DA, Cole B, Lewis J, et al. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. *Pain Med*. 2008;9(4):444-59. [Article](#)

⁷ Højsted J, Nielsen PR, Guldstrand SK, et al. Classification and identification of opioid addiction in chronic pain patients. *Eur J Pain*. 2010;14(10):1014-20. [Abstract](#)

⁸ Højsted J, Sjøgren P. Addiction to opioids in chronic pain patients: a literature review. *Eur J Pain*. 2007;11(5):490-518. [Abstract](#)

⁹ Hoffmann NG, Olofsson O, Salen B, Wickstrom L. Prevalence of abuse and dependency in chronic pain patients. *Int J Addict*. 1995;30(8):919-27. [Abstract](#)

¹⁰ Jonasson U, Jonasson B, Wickström L, et al. Analgesic use disorders among orthopedic and chronic pain patients at a rehabilitation clinic. *Subst Use Misuse*. 1998;33(6):1375-85. [Abstract](#)

¹¹ Juurlink DN, Dhalla IA. Dependence and addiction during chronic opioid therapy. *J Med Toxicol*. 2012;8(4):393-9. [Article](#)

¹² Kouyanou K, Pither CE, Wessely S. Medication misuse, abuse and dependence in chronic pain patients. *J Psychosom Res*. 1997;43(5):497-504. [Abstract](#)

- ¹³ Minozzi S, Amato L, Davoli M. Development of dependence following treatment with opioid analgesics for pain relief: a systematic review. *Addiction*. 2012;108(4):688-98. [Article](#)
- ¹⁴ Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. *Cochrane Database Syst Rev*. 2010 Jan 20;(1):CD006605. [Abstract](#)
- ¹⁵ Reid MC, Engles-Horton LL, Weber MB, et al. Use of opioid medications for chronic noncancer pain syndromes in primary care. *J Gen Intern Med*. 2002;17(3):173-9. [Article](#)
- ¹⁶ Bohnert ASB, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related death rated. *JAMA*. 2011;305(13):1315-21. [Article](#)
- ¹⁷ Lanas A, Perez-Aisa MA, Feu F, et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. *Am J Gastroenterol*. 2005;100(8):1685-93. [Abstract](#)
- ¹⁸ Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. *Ann Int Med*. 2010;152(2):85-92. [Article](#)
- ¹⁹ Paulozzi LJ, Kilbourne EM, Shah NG, et al. History of being prescribed controlled substances and risk of drug overdose death. *Pain Med*. 2012;13(1):87-95. [Article](#)
- ²⁰ Dasgupta N, Funk MJ, Proescholdbell S, et al. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. *Pain Med*. 2016;17:85-98. [Article](#)
- ²¹ Gomes T, Mamdani MM, Dhalla IA, et al. Opioid dose and drug-related mortality in patients with nonmalignant pain. *Arch Intern Med*. 2011;171(7):686-91. [Abstract](#)
- ²² Dunn C, Deroo L, Rivara FP. The use of brief interventions adapted from motivational interviewing across behavioral domains: a systematic review. *Addiction*. 2001;96(12):1725-42. [Abstract](#)
- ²³ Rubak S, Sandbaek A, Lauritzen T, Christensen B. Motivational interviewing: a systematic review and meta-analysis. *Br J Gen Pract*. 2005;55(513):305-12. [Abstract](#)
- ²⁴ Alperstein D, Sharpe L. The efficacy of motivational interviewing in adults with chronic pain: a meta-analysis and systematic review. *J Pain*. 2016;17(4):393-403. [Abstract](#)
- ²⁵ DeVeugh-Geiss A, Kadakia A, Baumgartner E, et al. Association between prescribed opioid dose and risk of overdose events - evaluation of dose-risk response in relation to potential confounding factors. *Pain Week Abstracts*. 2013;28:51-2. [Link to Abstract](#)
- ²⁶ Garg RK, Fulton-Kehoe D, Franklin GM. Patterns of opioid use and risk of opioid overdose death among medicaid patients. *Med Care*. 2017;55(7):661-668. [Abstract](#)
- ²⁷ Zedler B, Lin X, Wang L, et al. Risk factors for serious prescription opioid-related toxicity or overdose among Veterans Health Administration patients. *Pain Med*. 2014;15:1911-29. [Article](#)

- ²⁸ Edlund MJ, Martin BC, Russo JE, et al. Role of opioid prescription in incident opioid abuse and dependence among individuals with chronic non-cancer pain: role of opioid prescription. *Clin J Pain*. 2014;30(7):557-64. [Article](#)
- ²⁹ DeVeaugh-Geiss A, Coplan P, Kadakia A, Chilcoat H. Clinical characteristics of opioid overdose cases identified in a large commercially insured population. *Pain Week Abstracts*. 2013;27:49-50. [Link to Abstract](#)
- ³⁰ Fulton-Kehoe D, Garg RK, Turner JA, et al. Opioid poisonings and opioid adverse effects in workers in Washington state. *Am J Ind Med*. 2013;56(12):1452-62. [Abstract](#)
- ³¹ Ilgen MA, Kleinberg F, Ignacio RV, et al. Noncancer pain conditions and risk of suicide. *JAMA Psychiatry*. 2013;70(7):692-7. [Abstract](#)
- ³² Ilgen MA¹, Zivin K, Austin KL, et al. Severe pain predicts greater likelihood of subsequent suicide. *Suicide Life Threat Behav*. 2010;40(6):597-608. [Abstract](#)
- ³³ Madadi P, Persaud N. Suicide by means of opioid overdose in patients with chronic pain. *Curr Pain Headache Rep*. 2014;18(11):460. [Abstract](#)
- ³⁴ Spiegel B, Schoenfeld P, Naliboff B. Systematic review: the prevalence of suicidal behavior in patients with chronic abdominal pain and irritable bowel syndrome. *Aliment Pharmacol Ther*. 2007;26(2):183-93. [Abstract](#)
- ³⁵ Tang NK, Crane C. Suicidality in chronic pain: a review of the prevalence, risk factors and psychological links. *Psychol Med*. 2006;36(5):575-86. [Abstract](#)
- ³⁶ [Kline 2017 Suicide anecdotes related to opioid reductions 2015-7](#)
- ³⁷ [International Pain Foundation 2017 CDC opioid guideline outcome survey - iPain](#)
- ³⁸ Yarborough BJ, Stumbo SP, Janoff SL, et al. Understanding opioid overdose characteristics involving prescription and illicit opioids: a mixed methods analysis. *Drug Alcohol Depend*. 2016;167:49-56. [Abstract](#)
- ³⁹ Beaudoin FL, Banerjee GN, Mello MJ. State-level and system-level opioid prescribing policies: The impact on provider practices and overdose deaths, a systematic review. *J Opioid Manag*. 2016;12(2):109-18. [Abstract](#)
- ⁴⁰ Passik SD, Messina J, Golsorkhi A, Xie F. Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain. *J Pain Symptom Manage*. 2010;41:116-25. [Abstract](#)
- ⁴¹ Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. *JAMA*. 2008;300(22):2613-20. [Abstract](#)
- ⁴² Paulozzi LJ, Logan JE, Hall AJ, et al. A comparison of drug overdose deaths involving methadone and other opioid analgesics in West Virginia. *Addiction*. 2009;104(9):1541-8. [Abstract](#)

- ⁴³ Fudin J, Marcoux MD, Fudin JA. Mathematical model for methadone conversion examined. *Prac Pain Manage*. 2012 Sept; 46-51. [Article](#)
- ⁴⁴ Smith HS, Peppin JF. Toward a systematic approach to opioid rotation. *J Pain Res*. 2014;7:589-608. [Article](#)
- ⁴⁵ Mercadante S, Caraceni A. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. *Palliat Med*. 2011;25(5):504-15. [Abstract](#)
- ⁴⁶ O'Bryant CL, Linnebur SA, Yamashita TE, Kutner JS. Inconsistencies in opioid equianalgesic ratios: clinical and research implications. *J Pain Palliat Care Pharmacother*. 2008;22(4):282-90. [Abstract](#)
- ⁴⁷ Patanwala AE, DUBY J, Waters D, Erstad BL. Opioid conversions in acute care. *Ann Pharmacother*. 2007;41(2):255-66. [Abstract](#)
- ⁴⁸ Periera J, Lawlor P, Vigano A, et al. Equianalgesic dose ratios for opioids. a critical review and proposals for long-term dosing. *J Pain Symptom Manage*. 2001;22(2):672-87. [Abstract](#)
- ⁴⁹ Shaheen PE, Walsh D, Lasheen W, et al. Opioid equianalgesic tables: are they all equally dangerous? *J Pain Symptom Manage*. 2009;38(3):409-17. [Abstract](#)
- ⁵⁰ Webster LR, Fine PG. Review and critique of opioid rotation practices and associated risks of toxicity. *Pain Med*. 2012;13(4):562-70. [Abstract](#)
- ⁵¹ Shaw K, Fudin J. Evaluation and comparison of online equianalgesic opioid dose conversion calculators. *Prac Pain Manag*. 2013;13(7):61-66. [Article](#)
- ⁵² Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. *J Pain Symptom Manage*. 2003;26(5):1026-48. [Article](#)
- ⁵³ Miller M, Barber CW, Leatherman S, et al. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. *JAMA Intern Med*. 2015;175(4):608-15. [Abstract](#)
- ⁵⁴ Mack KA, Zhang K, Paulozzi L, Jones C. Prescription practices involving opioid analgesics among Americans with Medicaid, 2010. *J Health Care Poor Underserved*. 2015;26(1):182-98. [Article](#)
- ⁵⁵ Ray WA, Chung CP, Murray KT, et al. Out-of-hospital mortality among patients receiving methadone for noncancer pain. *JAMA Intern Med*. 2015;175(3):420-7. [Article](#)
- ⁵⁶ Paulozzi LJ, Mack KA, Jones CM. Vital Signs: Risk for overdose from methadone used for pain relief - US, 1999-2010. *MMWR Weekly*. 2012;61(26):493-7. [Article](#)
- ⁵⁷ Krebs EE, Becker WC, Zerzan J, et al. Comparative mortality among Department of Veterans Affairs patients prescribed methadone or long-acting morphine for chronic pain. *Pain*. 2011;152(8):1789-95. [Abstract](#)

- ⁵⁸ Hartung DM, Middleton L, Haxby DG, et al. Rates of adverse events of long-acting opioids in a state Medicaid program. *Ann Pharmacother*. 2007;41(6):921-8. [Abstract](#)
- ⁵⁹ Kirsh K, Peppin J, Coleman J. Characterization of prescription opioid abuse in the United States: focus on route of administration. *J Pain Palliat Care Pharmacother*. 2012;26(4):348-61. [Abstract](#)
- ⁶⁰ Gudin J. Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics: considerations for palliative care practice. *J Pain Palliat Care Pharmacother*. 2012;26(2):136-43. [Abstract](#)
- ⁶¹ Iwanicki JL, Severtson SG, McDaniel H, et al. Abuse and diversion of immediate release opioid analgesics as compared to extended release formulations in the United States. *PLoS One*. 2016;11(12):e0167499. [Article](#)
- ⁶² Cepeda MS, Coplan PM, Kopper NW, et al. ER/LA opioid analgesics REMS: overview of ongoing assessments of its progress and its impact on health outcomes. *Pain Med*. 2017;18(1):78-85. [Article](#)
- ⁶³ [No authors listed] Long Acting Opioid for Chronic Non-cancer Pain: a Review of the Clinical Efficacy and Safety. Canadian Agency for Drugs and Technologies. 2015 Aug. [Document](#)
- ⁶⁴ Argoff CE, Silvershein DI. A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. *Mayo Clin Proc*. 2009;84:602-12. [Article](#)
- ⁶⁵ Manchikanti L, Atluri S, Hirsch JA. The effect of abuse-deterrent extended-release oxycodone leads to inappropriate conclusions with over estimation of safety of abuse-deterrent formulations. *Pain Physician*. 2015;18(3):E445-6. [Article](#)
- ⁶⁶ Larochelle MR, Zhang R, Ross-Degnan D, Wharam F. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene. *JAMA Intern Med*. 2015;175(6):978-87. [Abstract](#)
- ⁶⁷ Argoff CE, Kahan M, Sellers EM. Preventing and managing aberrant drug-related behavior in primary care: systematic review of outcomes evidence. *J Opioid Manag*. 2014;10(2):119-34. [Abstract](#)
- ⁶⁸ Severtson SG, Ellis MS, Kurtz SP, et al. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone. *Drug Alcohol Depend*. 2016;168:219-229. [Article](#)
- ⁶⁹ Cassidy TA, DasMahapatra P, Black RA, et al. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent formulation. *Pain Med*. 2014;15(3):440-51. [Abstract](#)
- ⁷⁰ Cicero TJ, Ellis MS. Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: Lessons learned from OxyContin. *JAMA Psych*. 2015;72:424-9. [Abstract](#)
- ⁷¹ Webster LR, Reisfield GM, Dasgupta N. Eight principles for safer opioid prescribing and cautions with benzodiazepines. *Postgrad Med*. 2015;127(1):27-32. [Abstract](#)

- ⁷² Gudin JA, Mogali S, Jones JD, Comer SD. Risks, management, and monitoring of combination opioid, benzodiazepines, and / or alcohol use. *Postgrad Med*. 2013;125(4):115-30. [Article](#)
- ⁷³ Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. *Drug Alcohol Depend*. 2012;125(1-2):8-18. [Article](#)
- ⁷⁴ Gerlach LB, Olsson M, Kales HC, Maust DT. Opioids and other central nervous system-active polypharmacy in older adults in the United States. *J Am Geriatr Soc*. 2017 May 7. [Abstract](#)
- ⁷⁵ Guimmarra MJ, Gibson SJ, Allen AR, et al. Polypharmacy and chronic pain: harm exposure is not all about the opioids. *Pain Med*. 2015;16(3):472-9. [Abstract](#)
- ⁷⁶ Hwang CS, Kang EM, Kornegay CJ, et al. Trends in the concomitant prescribing of opioids and benzodiazepines, 2002-2014. *Am J Prev Med*. 2016;51(2):151-60. [Abstract](#)
- ⁷⁷ Sakshaug S, Handal M, Hjellvik V, et al. Long-term use of Z-hypnotics and co-medication with benzodiazepines and opioids. *Basic Clin Pharmacol Toxicol*. 2017;120(3):292-8. [Abstract](#)
- ⁷⁸ Sun EC, Dixit A, Humphreys K et al. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. *BMJ*. 2017;356:j760. [Article](#)
- ⁷⁷ Ashton H. The Ashton Manual. 2002. [Document](#)
- ⁸⁰ Landry MJ, Smith DE, McDuff DR, Baughman OL. Benzodiazepine dependence and withdrawal: identification and medical management. *J Am Board Fam Pract*. 1992;5(2):167-75. [Abstract](#)
- ⁸¹ Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013. *Am J Pub Health*. 2016;106:686-8. [Article](#)
- ⁸² Manchikanti L, Manchukonda R, Pampati V, et al. Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? *Pain Physician*. 2006; 9:123-9. [Article](#)
- ⁸³ Pesce A, West C, Gonzales E, et al. Illicit drug use correlates with negative urine drug test results for prescribed hydrocodone, oxycodone, and morphine. *Pain Phys*. 2012;15(5):E687-92. [Article](#)
- ⁸⁴ Christo PJ, Manchikanti L, Ruan X, et al. Urine drug testing in chronic pain. *Pain Physician*. 2011;14:123-43. [Article](#)
- ⁸⁵ Gourlay DL, Heit HA, Coplan YH, et al. Urine drug testing in clinical practice. 2015. PharmaCon Corp. [Monograph](#)
- ⁸⁶ Owen GT, Burton AW, Schade CM, Passik S. Urine drug testing: current recommendations and best practices. *Pain Phys*. 2012;15:ES119-33. [Article](#)